Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.46 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.42 |
| ▸ | ADH1B | P00325 | 1/20 | 0.40 |
| ▸ | ADH1C | P00326 | 1/20 | 0.40 |
| ▸ | ADH1A | P07327 | 1/20 | 0.40 |
| ▸ | ADH4 | P08319 | 1/20 | 0.40 |
| ▸ | ADH7 | P40394 | 1/20 | 0.40 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.39 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.38 |
| ▸ | FDPS | P14324 | 3/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20821296 | 1.00 | LMNA (0.54) | LMNAOPRM1SPHK1TSHRTHRB | |
| SCHEMBL5683598 | 1.00 | LMNA (0.54) | LMNAOPRM1SPHK1TSHRTHRB | |
| SCHEMBL23172791 | 0.97 | LMNA (0.52) | LMNAOPRM1SPHK1TSHRTHRB | |
| SCHEMBL6554193 | 0.95 | LMNA (0.48) | LMNAOPRM1SPHK1TSHRTHRB | |
| SCHEMBL22471932 | 0.95 | LMNA (0.54) | LMNAOPRM1SPHK1TSHRTHRB | |
| SCHEMBL17135388 | 0.92 | LMNA (0.50) | LMNAOPRM1SPHK1TSHRTHRB | |
| SCHEMBL5142110 | 0.90 | LMNA (0.50) | LMNAOPRM1SPHK1TSHRTHRB | |
| SCHEMBL9205053 | 0.90 | LMNA (0.50) | LMNAOPRM1SPHK1TSHRTHRB | |
| SCHEMBL9211183 | 0.90 | LMNA (0.50) | LMNAOPRM1SPHK1TSHRTHRB | |
| SCHEMBL671342 | 0.89 | ALDH1A1 (0.46) | LMNAOPRM1TSHRDNM1FDPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260092120-A1 | COMPOSITIONS AND METHODS | FLAGSHIP PIONEERING INNOVATIONS VII LLC (US) | 2026-04-02 | — | — | US | disclosed |
| EP-4695392-A2 | TREM COMPOSITIONS AND METHODS OF USE | Flagship Pioneering Innovations VI, LLC (US) | 2026-02-18 | — | — | EP | disclosed |
| EP-4695391-A1 | TREMS FOR USE IN CORRECTION OF MISSENSE MUTATIONS | Flagship Pioneering Innovations VI, LLC (US) | 2026-02-18 | — | — | EP | disclosed |
| EP-4684023-A2 | MODIFIED TEMPLATE GUIDE RNA MOLECULES | Tessera Therapeutics, Inc. (US) | 2026-01-28 | — | — | EP | disclosed |
| EP-4665405-A1 | DNA COMPOSITIONS COMPRISING MODIFIED URACIL | Flagship Pioneering Innovations VII, LLC (US) | 2025-12-24 | — | — | EP | disclosed |
| EP-4665856-A2 | DNA COMPOSITIONS COMPRISING MODIFIED CYTOSINE | Flagship Pioneering Innovations VII, LLC (US) | 2025-12-24 | — | — | EP | disclosed |
| WO-2025235506-A2 | ATP7B-MODULATING COMPOSITIONS AND METHODS | FLAGSHIP PIONEERING INNOVATIONS VI, LLC (US) | 2025-11-13 | — | — | WO | disclosed |
| US-20250277224-A1 | COMPOSITIONS AND METHODS FOR PRODUCING CIRCULAR POLYRIBONUCLEOTIDES | FLAGSHIP PIONEERING INNOVATIONS VI, LLC | 2025-09-04 | — | — | US | disclosed |
| EP-4598946-A1 | NUCLEIC ACID MOLECULES ENCODING TRIF AND ADDITIONALPOLYPEPTIDES AND THEIR USE IN TREATING CANCER | Flagship Pioneering Innovations V, Inc. (US) | 2025-08-13 | — | — | EP | disclosed |
| EP-4581012-A2 | NOVEL IONIZABLE LIPIDS AND LIPID NANOPARTICLES AND METHODS OF USING THE SAME | Sail Biomedicines, Inc. (US) | 2025-07-09 | — | — | EP | disclosed |
| WO-2023039424-A2 | METHODS AND COMPOSITIONS FOR MODULATING A GENOME | FLAGSHIP PIONEERING INNOVATIONS VI, LLC (US) | 2023-03-16 | — | — | WO | disclosed |
| WO-2023039440-A2 | HBB-MODULATING COMPOSITIONS AND METHODS | FLAGSHIP PIONEERING INNOVATIONS VI, LLC (US) | 2023-03-16 | — | — | WO | disclosed |
| WO-2023039407-A2 | METHODS AND COMPOSITIONS FOR MODULATING A GENOME | FLAGSHIP PIONEERING INNOVATIONS VI, LLC (US) | 2023-03-16 | — | — | WO | disclosed |
| EP-4114928-A1 | HOST DEFENSE SUPPRESSING METHODS AND COMPOSITIONS FOR MODULATING A GENOME | Flagship Pioneering Innovations VI, LLC (US) | 2023-01-11 | — | — | EP | disclosed |
| EP-4114941-A2 | IMPROVED METHODS AND COMPOSITIONS FOR MODULATING A GENOME | Flagship Pioneering Innovations VI, LLC (US) | 2023-01-11 | — | — | EP | disclosed |
| EP-4114940-A1 | METHODS AND COMPOSITIONS FOR MODULATING A GENOME | Flagship Pioneering Innovations VI, LLC (US) | 2023-01-11 | — | — | EP | disclosed |
| WO-2022212784-A1 | THANOTRANSMISSION POLYPEPTIDES AND THEIR USE IN TREATING CANCER | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2022-10-06 | — | — | WO | disclosed |
| WO-2022198014-A1 | LTR TRANSPOSON COMPOSITIONS AND METHODS | FLAGSHIP PIONEERING INNOVATIONS VI, LLC (US) | 2022-09-22 | — | — | WO | disclosed |
| WO-2022192863-A1 | LENTIVIRUS WITH ALTERED INTEGRASE ACTIVITY | FLAGSHIP PIONEERING INNOVATIONS VI, LLC (US) | 2022-09-15 | — | — | WO | disclosed |
| EP-3999642-A1 | RECOMBINASE COMPOSITIONS AND METHODS OF USE | Flagship Pioneering Innovations VI, LLC (US) | 2022-05-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260092120-A1 | COMPOSITIONS AND METHODS | TNFSF11, TNFSF10, CD14 | LMNA 2222/4885OPRM1 3222/4885SPHK1 4445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.